Davidson & Garrard’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q3
$4.13M Sell
121,896
-14,624
-11% -$470K 0.97% 38
2017
Q2
$4.35M Sell
136,520
-25,304
-16% -$798K 1.04% 33
2017
Q1
$5.25M Sell
161,824
-16,971
-9% -$535K 1.25% 25
2016
Q4
$5.51M Sell
178,795
-2,232
-1% -$68.1K 1.37% 22
2016
Q3
$5.82M Buy
181,027
+9,198
+5% +$308K 1.44% 20
2016
Q2
$5.74M Buy
171,829
+5,119
+3% +$163K 1.41% 18
2016
Q1
$4.69M Buy
166,710
+25,755
+18% +$736K 1.2% 29
2015
Q4
$4.32M Buy
140,955
+8,835
+7% +$278K 1.07% 30
2015
Q3
$3.94M Sell
132,120
-1,804
-1% -$57.8K 1.02% 33
2015
Q2
$4.26M Sell
133,924
-135
-0.1% -$4.4K 0.99% 33
2015
Q1
$4.42M Buy
134,059
+7,560
+6% +$240K 1.01% 36
2014
Q4
$3.74M Buy
126,499
+977
+0.8% +$28K 0.87% 44
2014
Q3
$3.52M Sell
125,522
-1,051
-0.8% -$29.5K 0.86% 42
2014
Q2
$3.56M Buy
126,573
+2,825
+2% +$80.5K 0.86% 44
2014
Q1
$3.77M Sell
123,748
-3,694
-3% -$110K 0.94% 38
2013
Q4
$3.7M Buy
127,442
+2,579
+2% +$75.1K 0.94% 40
2013
Q3
$3.4M Buy
124,863
+6,622
+6% +$180K 0.96% 40
2013
Q2
$3.14M Buy
+118,241
New +$3.27M 0.94% 42

Other funds holding PFE

Davidson & Garrard's PFE Position: Q3 2017 in Review

Davidson & Garrard reduced its Pfizer (PFE) stake by 11% in Q3 2017, selling an estimated $470K and leaving 121,896 shares worth $4.13M. The position accounts for 0.97% of the portfolio, ranked #38.

Davidson & Garrard first reported a position in PFE in Q2 2013 and has held it in 18 quarters since. The position peaked at $5.82M in Q3 2016. 2,040 funds tracked by Wall St. Rank hold PFE as of Q3 2017.

  • Davidson & Garrard held 121,896 shares of Pfizer worth $4.13M as of Q3 2017.
  • Davidson & Garrard sold 14,624 Pfizer shares in Q3 2017, an estimated $470K.
  • Pfizer made up 0.97% of Davidson & Garrard's portfolio in Q3 2017, its #38 holding.
  • Davidson & Garrard first reported a position in Pfizer in Q2 2013 and has held it in 18 quarters since.
  • Davidson & Garrard's Pfizer position peaked at $5.82M in Q3 2016.
  • 2,040 funds tracked by Wall St. Rank held Pfizer as of Q3 2017.

Based on Davidson & Garrard's 13F filing for Q3 2017, filed 7 Nov 2017.